https://doi.org/10.1016/j.breast.2018.12.014
L
Laura Pizzuti
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
198
Papers
4.0K
Citations
36
h-index
93
i10-index
Laura Pizzuti is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 36, co-authored 169 publications.
ORCID: 0000-0002-1696-2402Papers by this author
worksCombination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
2019 · The Breast · 170 citations
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
2020 · International Journal of Molecular Sciences · 73 citations
https://doi.org/10.3390/ijms21103528
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
2020 · Journal of Experimental & Clinical Cancer Research · 72 citations
https://doi.org/10.1186/s13046-020-01797-3
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
2014 · Breast Cancer Research and Treatment · 49 citations
https://doi.org/10.1007/s10549-014-3133-1
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
2021 · Scientific Reports · 43 citations
https://doi.org/10.1038/s41598-021-92774-z
The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy
2014 · Oncotarget · 39 citations
https://doi.org/10.18632/oncotarget.2449
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat